Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib added to endocrine therapy in advanced breast cancer
NCT00525161Phase 2Terminated
- Sponsor
- Suleiman Massarweh
- Start
- Oct 2007
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in breast cancer, sponsored by Suleiman Massarweh. Started Oct 2007; status: terminated.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00525161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00525161.